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Abstract
Background: Penicillin-binding proteins (PBPs) are well known and validated targets for antibacterial therapy. The most
important clinically used inhibitors of PBPs b-lactams inhibit transpeptidase activity of PBPs by forming a covalent
penicilloyl-enzyme complex that blocks the normal transpeptidation reaction; this finally results in bacterial death. In some
resistant bacteria the resistance is acquired by active-site distortion of PBPs, which lowers their acylation efficiency for b-
lactams. To address this problem we focused our attention to discovery of novel noncovalent inhibitors of PBPs.
Methodology/Principal Findings: Our in-house bank of compounds was screened for inhibition of three PBPs from
resistant bacteria: PBP2a from Methicillin-resistant Staphylococcus aureus (MRSA), PBP2x from Streptococcus pneumoniae
strain 5204, and PBP5fm from Enterococcus faecium strain D63r. Initial hit inhibitor obtained by screening was then used as a
starting point for computational similarity searching for structurally related compounds and several new noncovalent
inhibitors were discovered. Two compounds had promising inhibitory activities of both PBP2a and PBP2x 5204, and good
in-vitro antibacterial activities against a panel of Gram-positive bacterial strains.
Conclusions: We found new noncovalent inhibitors of PBPs which represent important starting points for development of
more potent inhibitors of PBPs that can target penicillin-resistant bacteria.
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Introduction
b-lactams (penicillins, cephalosporins and carbapenems) are the
most widely used antibiotics, due to their high effectiveness, low
cost, ease of use, and minimal side effects. At the molecular level,
b-lactams target the transpeptidase activity of penicillin-binding
proteins (PBPs) that are involved in bacterial cell-wall biosynthe-
sis[1]. In the presence of these antibiotics, the PBPs form a lethal
covalent penicilloyl-enzyme complex that blocks the normal
transpeptidation reaction; this finally results in bacterial death.
However, Gram-negative bacteria have acquired resistance to b-
lactams mainly through three different strategies: production of a
specific b-lactam hydrolase (the wide-spread b-lactamases);
presence of low-affinity PBPs; and active expulsion of b-lactams
via efflux pumps[2]. There is thus an urgent need to develop new
antibiotics to overcome the challenge of bacterial resistance to
existing antimicrobials.
Methicillin-resistant Staphylococcus aureus (MRSA) is a leading
cause of hospital- and community-acquired bacterial infection,
and is a global health threat[3,4]. Methicillin resistance in
MRSA strains has arisen from acquisition of the mecA gene,
which encodes a novel b-lactam-insensitive PBP (PBP2a)[5].
The crystal structure of PBP2a in both its apo form and
complexed to b-lactams has shown that methicillin resistance is
achieved through a distorted active site, which requires an
energetically costly b3 strand movement to allow acylation by b-
lactam antibiotics[6]. One of the possibilities to overcome this
intrinsic poor acylation efficiency of PBP2a is to design new b-
lactams that have improved binding affinities due to increased
noncovalent interactions between the inhibitor and the active
site. On the other hand, noncovalent compounds that bind
tightly to the active site without acylation might also pro-
vide highly effective inhibitors. Noncovalent inhibitors will not
require the unfavorable conformational changes in the active
site of PBP2a that are required for acylation, and they will
hopefully also not be susceptible to b-lactamases[1,6]. To date,
only a few noncovalent inhibitors of PBPs have been
described[7–9], and so we screened our in-house bank of
compounds for potential inhibition of this important drug
target.
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Screening with a series of more than 250 compounds belonging
to different nonreactive chemical classes allowed us to identify an
initial hit in compound 1 (Figure 1), which inhibited PBP2a with a
promising IC50 of 97 mM (Table 1). To obtain a small focused
library of structurally related compounds for further studies,
computational similarity searches were performed based on the
structure of compound 1 as a starting point and using the
ChemBridge bank of compounds. The ZINC[10] built-in search
engine together with Ftrees 1.0 (BioSolveIT GmbH) software[11]
was used. Two different queries were used (query A (compound 1)
and query B, Figure 2) and Tanimoto similarity coefficient was set
to 0.90. The only difference between the queries is the bond
linking naphthalene ring with anthranilic acid: sulfonamide in
query A is replaced with an amide in query B. From the hits of
similarity search we selected only the compounds with unprotected
functional groups. Similarity search with FTrees gave compounds
2 and 3 while the rest were obtained by similarity search with
ZINC built-in search engine (Figure 1).
Additionally to screening on PBP2a, all of these compounds
were also evaluated for inhibition of two other PBPs: PBP2x from
the highly drug-resistant Streptococcus pneumoniae strain 5204[12],
and PBP5fm from the drug-resistant Enterococcus faecium strain D63r
(Table 1) [13]. All three of the enzymes used for screening are
resistant PBPs from important human-pathogen species that are
related to community and nosocomial infections, and that
therefore represent important drug targets. Similar to PBP2a,
resistance to penicillin in PBP2x 5204 and PBP5fm is acquired by
active-site distortion, which lowers their acylation efficiency for b-
lactams.
All of these compounds were evaluated biochemically in the
presence of detergent (Triton X-100), to exclude the formation of
detergent-sensitive promiscuous aggregates[14]. Identical results
were observed after 30 or 240 minutes of pre-incubation of the
enzyme with the compounds, suggesting rapid and noncovalent
inhibition. For the compounds that inhibited at least one of the
enzymes under investigation, in-vitro antibacterial activity was
determined using a panel of five Gram-negative and 15 Gram-
positive bacterial strains (Table 2).
As with PBP2a, compound 1 inhibited PBP2x 5204 with an
IC50 value of 391 mM. The importance of this hit compound is
further underlined by its very promising minimum inhibitory
concentrations (MICs) against several Gram-positive bacterial
strains, including MRSA (32 mg/mL). Indeed, this MIC value for
all of the Staphylococcus aureus tested strains (32 mg/ml or 80 mM) is
lower than the IC50 value observed for PBP2a (97 mM), suggesting
that in vivo compound 1 does not only inhibit PBP2a but could be
active on other different cellular targets. This assumption is
confirmed by the fact that for S. aureus ATCC25923 strain,
sensitive to penicillin and devoid of PBP2a, compound 1 has the
same MIC value as for the other two resistant S. aureus strains
(Table 2) where PBP2a is present. To better understand the
antibacterial activity of compound 1, we performed an experiment
to evaluate the effect of compound 1 on the protoplasts of S. aureus
ATCC43300 resistant strain, at a concentration equivalent to 4
times the MIC. After ten minutes, the complete lysis of protoplasts
was observed, strongly suggesting an effect of compound 1 on S.
aureus plasma membranes. Furthermore, killing curves experi-
ments, at equivalent concentration of compound 1, showed an
immediate decrease in the bacterial count, and no viable cells were
observed after 120 min, showing a fast bactericidal effect (data not
shown) presumably not solely related to the inactivation of PBPs.
This suggests that compound 1 may trigger additional cellular
events which positively contribute to the antibacterial activity.
Further analysis is needed to better understand the precise mode of
action of these inhibitors on the bacterial cell.
From the series of sulfonamide compounds 2–5, the only
inhibitor was the quinoline-8-sulfonamide derivative compound 2,
which inhibited PBP5fm. Although the IC50 was moderate and
compound 2 did not have significant antibacterial activity (MICs
above 512 mg/mL), it represents a very important hit compound, as
to the best of our knowledge, this is the first noncovalent inhibitor of
PBP5fm to be described. Promising inhibitors were also seen in the
series of anthranilic acid derivatives, compounds 6–12. 5-Bromo-2-
(4-propoxybenzamido) benzoic acid, compound 6, was a good
inhibitorof PBP2a (IC50, 210 mM) with lower inhibitionseen for the
other two enzymes, and a generally good in-vitro antimicrobial
activity against Gram-positive bacteria, even if its growth inhibition
of MRSA strains was only moderate. If the 5-bromo substituent was
replaced by a 5-hydroxy group or removed, the enzyme inhibitory
activity of compounds 7 and 8, respectively, significantly decreased.
Incompounds9–12,thepropoxy-substituentofthe benzamido part
of the inhibitors is at position 3. 5-Bromo-2-(3-propoxybenzami-
do)benzoic acid, compound 9, was a very promising inhibitor of
both PBP2a and PBP2x 5204 (IC50,2 3 0 mM and 155 mM,
respectively). Also, compound 9 showed good antibacterial activity
against Gram-positive bacterial strains, and in particular against E.
faecium and S. pneumoniae, as well as both sensitive and resistant S.
aureus. If the 5-bromo substituent was replaced by a methyl,
compound 10, inhibition of PBP2a was reduced three-fold and
inhibition of PBP2x 5204 was lost.
Consequently, the antibacterial activity of compound 10
decreased for all of the bacteria, with the exception of
pneumococcal strains, where surprisingly it remained unchanged.
Introduction of the hydroxyl group to position 5 in compound 11
further reduced the PBP inhibitory activity. The 5-unsubstituted
anthranilic acid derivative compound 12 was a moderate inhibitor
of PBP2a and PBP5fm (IC50, 910 mM and .1 mM, respectively).
The MICs were also consistent with poor PBP inhibitory activity,
as they were not better than 256 mg/mL for all of the bacterial
strains under investigation.
To hypothesize the binding modes of the two best inhibitors,
which could assist further structural optimization, inhibitors 1 and
9 were docked into the active sites of PBP2a (pdb code 1VQQ)
and PBP2x, respectively. Since there is no known crystal structure
of PBP2x 5204, the coordinates of the structurally related (97%
sequence identity, Figure 3) PBP2x Sp328 (pdb code 1K25) were
used as a template for building the model of PBP2x 5204. Sybyl
8.0 (Tripos Inc.) was used to replace amino acid residues that differ
between PBP2x Sp328 and PBP2x 5204. The homology built
model was then minimized so that there were no clashes between
side chains of the protein.
The docking study was performed using FlexX 3.0[15]. The
PBP2a active site contains a nucleophilic Ser403, while the
backbone nitrogens of Ser403 and Thr600 form a conserved
oxyanion hole, and Lys406 functions as a catalytic base[6]. These
data were used to define the size and position of the active-site
pocket in the docking experiments. The active site was defined as
the area within 10 A ˚ from Lys406. Figure 4 shows the predicted
binding conformation of inhibitor 1 in the active site of PBP2a.
Inhibitor 1 forms interactions with amino acids that have
previously been shown to be important for the binding of the
substrate[6]. The sulfonamide oxygen forms H-bonds with
Thr600, while the anthranilic acid phenyl ring binds to Lys406
through p-cation interactions. The naphthalene ring forms
hydrophobic interactions with Met641 and Tyr446 (not shown,
for clarity).
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(Ser337) in its active site, as well as two lysines (Lys340 and
Lys547) that can act as a catalytic base[16]. Active site was defined
as the area within 10 A ˚ from Lys340. Figure 5 shows the predicted
binding conformation of inhibitor 9 in the active site of PBP2x
5204. At least two H-bonds are possible: Ser337 and Asn397 form
H-bonds with the inhibitor 9 amide oxygen and nitrogen,
respectively. Both of the lysines of the active site form interactions
with the free carboxylic group of inhibitor 9. The binding affinity
here might be improved by introducing substituents to the position
5 of the anthranilic acid ring. For example, the bulky bromine can
be substituted by larger hydrophobic groups, such as isopropyl or
tert-butyl. In addition, by comparing the activity of compounds 6
and 9, which differ only in the position of the propyloxy
substituents, we can postulate that the proper position of this
substituent on benzoic acid ring appears to be position 3. This is in
agreement with our docking study, where unfavorable steric
clashes of 4-propyloxy group with the active site of PBP2x 5204
are possible in the case of the compound 6.
In conclusion, this screening of our in-house bank of compounds
followed by similarity searches performed on the ChemBridge
databank containing more than 800,000 compounds has led to the
identification of new noncovalent inhibitors of PBPs (PBP2a,
PBP2x 5204 and PBP5fm) from the penicillin-resistant bacterial
strains. Inhibitors 1 and 9 are shown to have promising inhibitory
activities of both PBP2a and PBP2x 5204, and good in-vitro
antibacterial activities against a panel of Gram-positive bacterial
strains. Therefore, inhibitors 1 and 9 represent important starting
Figure 1. Structures of compounds 1–12.
doi:10.1371/journal.pone.0019418.g001
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Computational part was done on workstation with 4 dual core
AMD Opteron 2,0 GHz processors, 16 GB of RAM, 4 320 GB
hard drives in RAID10 array and nVidia GeForce 7900 graphic
card. Workstation has Fedora 7 64 bit installed.
Similarity searching was done with ZINC [10] built-in engine
and with FTrees 1.0 (BioSolveIT GmbH) [11]. Queries A and B
were used with both search engines. In all cases ChemBridge bank
of compounds was used and Tanimoto similarity coefficient was
set to 0.90. Additionally Dynamic Match Search and Global Gap
Penalty were user for FTrees search.
Homology building was done with Sybyl 8.0 (Tripos Inc.).
Coordinates of PBP2x Sp328 (pdb code 1K25) were used as a
template for building the model of PBP2x 5204. Amino acid
residues that differ between the two PBPs were replaced. Replaced
amino acids were then minimized using Tripos Force Field.
Docking was done with FlexX 3.0 (BioSolveIT GmbH)[15]. For
docking in PBP2a we used crystal structure 1VQQ and for
docking in PBP2x 5204 we used our homology built model. Active
site was defined as the area within 10 A ˚ from Lys406 and Lys340
for PBP2a and PBP2x 5204 respectively. Docking parameters were
the same in both cases. For base placement Triangle Matching
was used and the program generated maximally 200 solutions per
iteration and 200 per fragmentation.
Chemistry
General. Chemicals were from Sigma-Aldrich and Acros
Organics, and were used without further purification. Solvents
were used without purification or drying, unless otherwise stated.
Analytical TLC was performed on Merck silica gel (60F254) plates
(0.25 mm), and the compounds were visualized with ultraviolet
light. Column chromatography was carried out on silica gel 60
(particle size, 240–400 mesh). Melting points were determined on
a Reichert hot-stage microscope and are uncorrected.
1H-NMR
spectra were recorded on a Bruker AVANCE DPX300
spectrometer in CDCl3 or DMSO-d6 solution, with TMS as the
internal standard. IR spectra were obtained on a Perkin-Elmer
1600 FT-IR spectrometer. Microanalyses were performed on
a Perkin-Elmer C, H, N analyzer 240 C. Mass spectra were
obtained using a VG-Analytical Autospec Q mass spectrometer.
Synthesis of compound 1. 6-Butoxynaphthalenesulfonyl
chloride 14 was prepared according to the three-step procedure
previously described (Scheme 1)[17]. In the next step it was
coupled with methyl anthranilate to give sulfonamide 15. The
target compound 1 was obtained after the final hydrolysis with
1 M NaOH/dioxane (Figure 6).
Procedure for the preparation of methyl 2-(6-
butoxynaphthalene-2-sulfonamido)benzoate (15). To an
ice-cold solution of methyl anthranilate (2.04 mmol, 309.4 mg)
in dry CH2Cl2 (5 mL), Et3N (2.5 mmol, 505 mg) and a solution of
compound 14 (1.0 mmol, 597.0 mg) in CH2Cl2 (5 mL) were
slowly added. The reaction mixture was stirred at 0uC for 30 min
and then at room temperature for 24 h. After the reaction was
complete (monitored by TLC), 1 M HCl (15 mL) was added and
the mixture extracted with CH2Cl2 (3620 mL). The combined
Figure 2. Query A and query B used for computational similarity search.
doi:10.1371/journal.pone.0019418.g002
Table 1. New inhibitors of PBPs from resistant bacteria.
a
Compound PBP2a RA [%] (IC50) PBP2x5204 RA [%] (IC50) PBP5fm RA [%] (IC50)
1 0 (97 mM) 38
b (391 mM) 100
2 58 123 39 (930 mM)
36 7 8 0 6 5
4 83 101 100
58 6 8 1 7 3
6 0 (210 mM) 41 68
77 4 6 5 7 2
86 0 1 0 3 7 4
9 0 (230 mM) 8
b (155 mM) 72
10 17 (680 mM) 121 69
11 70 118 61
12 47 (910 mM) 97 34 (.1 mM)
aThe data represent mean values of three independent experiments. Standard deviations were within 610% of these mean values. RA=residual activity of the enzyme
at 1 mM inhibitor, unless stated otherwise. IC50-values were determined in the presence of 0.01% Triton X-100.
bResidual activity of the enzyme at 500 mM inhibitor.
doi:10.1371/journal.pone.0019418.t001
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Na2SO4, filtered, and evaporated under reduced pressure. The
residue was purified by silica gel column chromatography (EtOAc-
hexane=1/3), to provide a white solid, 310 mg (75%), which was
immediately used in the next step.
Procedure for the preparation of 2-(6-butoxynaphthalene-
2-sulfonamido)benzoic acid (1). To a stirred solution of 15
(0.60 mmol, 250.0 mg) in dioxane (5 mL), 1 M NaOH (3 mL) was
slowly added, and the reaction mixture stirred overnight at room
temperature. Then the reaction mixture was diluted with H2O
(20 mL) and washed with EtOAc (3620 mL). The aqueous phase
was acidified with 1 M HCl to pH 1, and extracted with EtOAc
(3620 mL). The combined organic layers were washed with brine
(2630 mL), dried over Na2SO4, filtered, and then the solvent was
removed under reduced pressure, to yield a white solid, 213 mg
(85%). Mp=192–194uC;
1H-NMR (300 MHz, CDCl3): d ppm
0.94 (t, J=7.5 Hz, 3H, -CH2CH3); 1.40–1.52 (m, 2H, -
OCH2CH2CH2CH3); 1.71–1.80 (m, 2H, -OCH2CH2CH2CH3);
4.11(t, J=6.6 Hz,2H,-OCH2); 7.05–7.10(m, 1H,Ar-H); 7.28 (dd,
J=9.0, 2.4 Hz, 1H, Ar-H); 7.41 (d, J=2.4 Hz, 1H, Ar-H); 7.48–
7.58 (m, 2H, Ar-H); 7.69 (dd, J=8.7, 2.1 Hz, 2H, Ar-H); 7.85–7.94
(m, 2H, Ar-H); 8.05 (d, J=9.0 Hz, 1H, Ar-H); 8.49 (d, J=1.8 Hz,
1H, Ar-H); 11.18 (br s, 1H, -SO2NH-); 13.95 (br s, 1H, -COOH);
EI-MS: m/z 399 (C21H21NO5S, M
+); CHN found C: 63.45, H:
5.50, N: 3.51; calc. for C21H21NO5S C: 63.14, H: 5.30, N: 3.51.
Purity of compounds 2–12. For compounds 2, 3, 5, 7, 8,
11, and 12, HPLC purity was determined using an Agilent Eclipse
C18 column (4.6650 mm, 5 mm) with a flow rate of 1.0 mL/min,
detection at 254 nm, and an eluent system of: A=H2O with 0.1%
TFA; B=MeOH. The following gradient was applied: 0–3 min,
30% B; 3–18 min, 30% BR80% B; 18–23 min, 80% B; 23–
30 min, 80% BR30% B; run time=30 min; T=25uC.
3-(Quinoline-8-sulfonamido)benzamide (2): Retention time:
5.59 min, HPLC purity: 99.06%.
N-(4-Hydroxyphenyl)quinoline-8-sulfonamide (3): Retention
time: 11.20 min, HPLC purity: 96.12%.
4-(4-Ethoxyphenylsulfonamido)benzoic acid (5): Retention time:
13.86 min, HPLC purity: 99.56%.
5-Hydroxy-2-(4-propoxybenzamido)benzoic acid (7): Retention
time: 19.65 min, HPLC purity: 100.0%.
2-(4-Propoxybenzamido)benzoic acid (8): Retention time:
22.56 min, HPLC purity: 98.62%.
5-Hydroxy-2-(3-propoxybenzamido)benzoic acid (11): Reten-
tion time: 19.96 min, HPLC purity: 99.38%.
2-(3-Propoxybenzamido)benzoic acid (12): Retention time:
22.92 min, HPLC purity: 99.41%.
Purity for compounds 4, 6, 9 and 10 was determined with
elemental analysis.
4-(N-(4-Ethoxyphenyl)sulfamoyl)benzoic acid (4): CHN found
C: 55.94, H: 4.79, N: 4.50; calc. for C15H15NO5S C: 56.06, H:
4.70, N: 4.36.
5-Bromo-2-(4-propoxybenzamido)benzoic acid (6): CHN found
C: 54.01, H: 4.13, N: 3.77; calc. for C17H16BrNO4 C: 53.99, H:
4.26, N: 3.70.
5-Bromo-2-(3-propoxybenzamido)benzoic acid (9): CHN found
C: 53.66, H: 4.22, N: 4.03; calc. for C17H16BrNO4 C: 53.99, H:
4.26, N: 3.70.
5-Methyl-2-(3-propoxybenzamido)benzoic acid (10): CHN
found C: 68.99, H: 5.96, N: 4.51; calc. for C18H19NO4 C:
68.99, H: 6.11, N: 4.47.
Biology
Enzymatic inhibition assays for low affinity PBP2a and
PBP5fm. PBP2a from Staphylococcus aureus ATCC 43300 and
Table 2. In-vitro antibacterial activities of inhibitors of PBPs from resistant species.
Bacterial Strain MIC (mg/mL)
1 2 6 9 10 12 Ampicillin
Escherichia coli ATCC 8739 .1024 .512 .512 .512 .512 .512 4
Proteus mirabilis ATCC 29936 .1024 .512 .512 .512 .512 .512 2
Citrobacter freundii ATCC 8090 .1024 .512 .512 .512 .512 .512 128
Pseudomonas aeruginosa ATCC 27853 .1024 .512 .512 .512 .512 .512 .1024
Klebsiella pneumoniae ATCC 13883 .1024 .512 .512 .512 .512 .512 256
Micrococcus luteus ATCC 9341 2 .512 32 16 256 256 0.5
Listeria innocua ATCC 33090 16 .512 64 16 256 .512 0.25
Listeria monocytogenes ATCC 14780 16 .512 64 16 32 .512 0.5
Bacillus subtilis ATCC 6633 2 .512 128 32 256 .512 0.5
Enterococcus faecalis ATCC 7937 16 .512 64 64 256 .512 2
Enterococcus faecalis ATCC 29212 32 .512 32 64 256 256 2
Enterococcus faecium ATCC 19434 64 .512 256 16 128 .512 64
Enterococcus hirae ATCC 8790 16 .512 32 16 128 256 64
Streptococcus pneumoniae ATCC 49619 1 .512 32 1 2 256 0.06
Streptococcus pneumoniae ATCC 33400 1 .512 64 1 2 256 0.03
Streptococcus pneumoniae D39 1 .512 16 1 2 256 0.06
Staphylococcus epidermidis ATCC 12228 32 .512 16 8 128 256 16
Staphylococcus aureus ATCC 25923 32 .512 16 32 128 512 0.25
Staphylococcus aureus ATCC 43300 (MRSA) 32 .512 128 32 256 512 1024
Staphylococcus aureus mp 1 (inducible MRSA) 32 .512 128 32 256 512 1024
doi:10.1371/journal.pone.0019418.t002
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doi:10.1371/journal.pone.0019418.g003
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purified as described previously[13,18].
Each of the purified PBPs (2.5 mM) were first incubated with
1 mM potential inhibitor in 100 mM phosphate buffer, 0.01%
Triton X-100[19], pH 7, for 4 h at 30uC. Then, 25 mM flu-
orescein-labeled ampicillin[20] was added to detect the residu-
al penicillin binding activity (RA). The samples were further
incubated for 30 min at 37uC in a total volume of 20 mL.
Denaturation buffer was added (0.1 M Tris/HCl, pH 6.8,
containing 25% glycerol, 2% SDS, 20% b-mercaptoethanol and
0.02% bromophenol blue) and the samples were heated to 100uC
for 1 min. The samples were then loaded onto a 10% SDS-
acrilamide gel (1067 cm) and electrophoresis was performed for
45 min at 180 V (12 mA). Detection and quantification of the
RAs were with Molecular Image FX equipment and Quantity
One software (BioRad, Hercules, CA, USA). Three independent
experiments were carried out for each inhibitor.
Enzymatic inhibition assays for PBP2x 5204. PBP2x-5204
fromStreptococcus pneumonia[12] andN-benzoyl-D-alanyl-thioglycolate
S2d[21,22] were prepared as previously described. All assays with
PBP2x 5204 were carried out in 96-well microtiter plates (Brand,
Wertheim, Germany). PBP2x 5204 (0.6 mM) was incubated in the
Figure 4. Docking of the sulfonamide inhibitor 1. Inhibitor 1 (magenta) docked into the active site of PBP2a (pdb code 1vqq). The amino acids
that form interactions with inhibitor 1 are shown as green sticks.
doi:10.1371/journal.pone.0019418.g004
Figure 5. Docking of the anthranilic acid derivative inhibitor 9. Inhibitor 9 (magenta) docked into the active site of PBP2x 5204. The amino
acids that form interactions with inhibitor 9 are shown as green sticks.
doi:10.1371/journal.pone.0019418.g005
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buffer (pH 7.0) containing 70 mM D-alanine and 0.01 mg/mL
BSA, for 4 h at 25uC. This preincubation was used to also detect
slow binding inhibitors. After the preincubation, the RA of PBP2x
5204 was determined. The initial rate of hydrolysis of 1 mM S2d in
the presence of 1 mM DTNB was determined by monitoring the
increase in absorbance at 412 nm (DTNB:e[De ]=13600 M
21 s
21)
using a microplate absorbance reader (Power Wave X, Biotek
Instruments, Winooski, U.S.A.). The rate of spontaneous hydrolysis
ofS2d inthe presenceofthe potential inhibitors was also determined
in the absence of PBP2x 5204. All of the assays were carried out in
triplicate. The determination of the RA of PBP2x 5204 in the
absence of inhibitors was carried out six times on each plate. A test
compound was considered as an inhibitor if the RA was ,80%. In
this case, to reveal false positives, the assays were also carried out
under the same conditions in the presence of 0.01% Triton X-100.
As described in the literature, promiscuous inhibitors (false positives)
are slow binding, noncompetitive inhibitors. To avoid detailed
kinetic investigations[8], it is possible to identify such compounds by
carrying out the assays in the presence of Triton X-100[14,19].
Promiscuous inhibitors show no inhibition in the presence of Triton
X-100. The IC50 values in the presence of Triton X-100 were
determined if the RAs were ,50%. (RA: ,50%, IC50,c, c:
concentration of compound in the assay; RA .50%, IC50 . c). The
RA was measured over a range of concentrations, from which the
IC50 values were determined by non-linear regression analysis, using
Sigma Plot (Systat software) and fitting the data to the equation
y=y0+(a6b)/(b+x)[23].
Antibacterial activity. Determination of the antibacterial
activities was carried out on microtiter plates, in 200 mL (final
volume) of Mu ¨eller-Hinton Broth (MHB), following EUCAST
(European Committee on Antimicrobial Susceptibility testing)/
CLSI (Clinical and Laboratory Standard Institute) recommended
procedures[24,25]. The compounds were solubilized in MHB, just
before use. Inocula were prepared for each strain by resuspending
isolated colonies from 18 h cultured plates. Equivalents of 0.5 Mac
Farland turbidity standards (approximately 1610
8 CFU mL
21)
were prepared in saline solution (0.085% NaCl) and then diluted
200-fold in MBH. MICs were determined as the lowest dilution of
product that showed no visual turbidity.
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